Cholinergic augmentation of insulin release requires ankyrin-B

Jane A. Healy; Kent R. Nilsson; Hans E. Hohmeier; Jelena Berglund; Jonathan Davis; Janis Hoffman; Martin Kohler; Luo Sheng Li; Per Olof Berggren; Christopher B. Newgard; Vann Bennett

doi:10.1126/scisignal.2000771

Cholinergic augmentation of insulin release requires ankyrin-B

Jane A. Healy, Kent R. Nilsson, Hans E. Hohmeier, Jelena Berglund, Jonathan Davis, Janis Hoffman, Martin Kohler, Luo Sheng Li, Per Olof Berggren, Christopher B. Newgard, Vann Bennett

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Parasympathetic stimulation of pancreatic islets augments glucose-stimulated insulin secretion by inducing inositol trisphosphate receptor (IP ₃R)-mediated calcium ion (Ca ²⁺) release. Ankyrin-B binds to the IP ₃R and is enriched in pancreatic beta cells. We found that ankyrin-B-deficient islets displayed impaired potentiation of insulin secretion by the muscarinic agonist carbachol, blunted carbacholmediated intracellular Ca ²⁺ release, and reduced the abundance of IP ₃R. Ankyrin-B-haploinsufficient mice exhibited hyperglycemia after oral ingestion but not after intraperitoneal injection of glucose, consistent with impaired parasympathetic potentiation of glucose-stimulated insulin secretion. The R1788W mutation of ankyrin-B impaired its function in pancreatic islets and is associated with type 2 diabetes in Caucasians and Hispanics. Thus, defective glycemic regulation through loss of ankyrin-B-dependent stabilization of IP ₃R is a potential risk factor for type 2 diabetes.

Original language	English (US)
Pages (from-to)	ra19
Journal	Science Signaling
Volume	3
Issue number	113
DOIs	https://doi.org/10.1126/scisignal.2000771
State	Published - Mar 16 2010
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Cell Biology

Access to Document

10.1126/scisignal.2000771

Fingerprint Dive into the research topics of 'Cholinergic augmentation of insulin release requires ankyrin-B'. Together they form a unique fingerprint.

Cite this

Cholinergic augmentation of insulin release requires ankyrin-B. / Healy, Jane A.; Nilsson, Kent R.; Hohmeier, Hans E.; Berglund, Jelena; Davis, Jonathan; Hoffman, Janis; Kohler, Martin; Li, Luo Sheng; Berggren, Per Olof; Newgard, Christopher B.; Bennett, Vann.

In: Science Signaling, Vol. 3, No. 113, 16.03.2010, p. ra19.

Research output: Contribution to journal › Article › peer-review

@article{6c983ea60900441abd100a5e082d444a,

title = "Cholinergic augmentation of insulin release requires ankyrin-B",

abstract = "Parasympathetic stimulation of pancreatic islets augments glucose-stimulated insulin secretion by inducing inositol trisphosphate receptor (IP 3R)-mediated calcium ion (Ca 2+) release. Ankyrin-B binds to the IP 3R and is enriched in pancreatic beta cells. We found that ankyrin-B-deficient islets displayed impaired potentiation of insulin secretion by the muscarinic agonist carbachol, blunted carbacholmediated intracellular Ca 2+ release, and reduced the abundance of IP 3R. Ankyrin-B-haploinsufficient mice exhibited hyperglycemia after oral ingestion but not after intraperitoneal injection of glucose, consistent with impaired parasympathetic potentiation of glucose-stimulated insulin secretion. The R1788W mutation of ankyrin-B impaired its function in pancreatic islets and is associated with type 2 diabetes in Caucasians and Hispanics. Thus, defective glycemic regulation through loss of ankyrin-B-dependent stabilization of IP 3R is a potential risk factor for type 2 diabetes.",

author = "Healy, {Jane A.} and Nilsson, {Kent R.} and Hohmeier, {Hans E.} and Jelena Berglund and Jonathan Davis and Janis Hoffman and Martin Kohler and Li, {Luo Sheng} and Berggren, {Per Olof} and Newgard, {Christopher B.} and Vann Bennett",

year = "2010",

month = mar,

day = "16",

doi = "10.1126/scisignal.2000771",

language = "English (US)",

volume = "3",

pages = "ra19",

journal = "Science's STKE : signal transduction knowledge environment",

issn = "1937-9145",

publisher = "American Association for the Advancement of Science",

number = "113",

}

TY - JOUR

T1 - Cholinergic augmentation of insulin release requires ankyrin-B

AU - Healy, Jane A.

AU - Nilsson, Kent R.

AU - Hohmeier, Hans E.

AU - Berglund, Jelena

AU - Davis, Jonathan

AU - Hoffman, Janis

AU - Kohler, Martin

AU - Li, Luo Sheng

AU - Berggren, Per Olof

AU - Newgard, Christopher B.

AU - Bennett, Vann

PY - 2010/3/16

Y1 - 2010/3/16

N2 - Parasympathetic stimulation of pancreatic islets augments glucose-stimulated insulin secretion by inducing inositol trisphosphate receptor (IP 3R)-mediated calcium ion (Ca 2+) release. Ankyrin-B binds to the IP 3R and is enriched in pancreatic beta cells. We found that ankyrin-B-deficient islets displayed impaired potentiation of insulin secretion by the muscarinic agonist carbachol, blunted carbacholmediated intracellular Ca 2+ release, and reduced the abundance of IP 3R. Ankyrin-B-haploinsufficient mice exhibited hyperglycemia after oral ingestion but not after intraperitoneal injection of glucose, consistent with impaired parasympathetic potentiation of glucose-stimulated insulin secretion. The R1788W mutation of ankyrin-B impaired its function in pancreatic islets and is associated with type 2 diabetes in Caucasians and Hispanics. Thus, defective glycemic regulation through loss of ankyrin-B-dependent stabilization of IP 3R is a potential risk factor for type 2 diabetes.

AB - Parasympathetic stimulation of pancreatic islets augments glucose-stimulated insulin secretion by inducing inositol trisphosphate receptor (IP 3R)-mediated calcium ion (Ca 2+) release. Ankyrin-B binds to the IP 3R and is enriched in pancreatic beta cells. We found that ankyrin-B-deficient islets displayed impaired potentiation of insulin secretion by the muscarinic agonist carbachol, blunted carbacholmediated intracellular Ca 2+ release, and reduced the abundance of IP 3R. Ankyrin-B-haploinsufficient mice exhibited hyperglycemia after oral ingestion but not after intraperitoneal injection of glucose, consistent with impaired parasympathetic potentiation of glucose-stimulated insulin secretion. The R1788W mutation of ankyrin-B impaired its function in pancreatic islets and is associated with type 2 diabetes in Caucasians and Hispanics. Thus, defective glycemic regulation through loss of ankyrin-B-dependent stabilization of IP 3R is a potential risk factor for type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=77953844541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953844541&partnerID=8YFLogxK

U2 - 10.1126/scisignal.2000771

DO - 10.1126/scisignal.2000771

M3 - Article

C2 - 20234002

AN - SCOPUS:77953844541

VL - 3

SP - ra19

JO - Science's STKE : signal transduction knowledge environment

JF - Science's STKE : signal transduction knowledge environment

SN - 1937-9145

IS - 113

ER -

Cholinergic augmentation of insulin release requires ankyrin-B

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this